HBsAg, HBeAg and HCC prediction

HBsAg (Hepatitis B surface antigen) and HBeAg (Hepatitis B e antigen) are important biomarkers in understanding the progression and risk factors of chronic hepatitis B virus (HBV) infection, particularly in relation to hepatocellular carcinoma (HCC) prediction.

HBeAg and HCC Risk:

HBeAg status is a key indicator of the phase of chronic HBV infection. HBeAg-positive patients generally have higher HBV DNA levels and an increased risk of HCC compared to HBeAg-negative patients. However, the relationship between HBV DNA levels and HCC risk differs based on HBeAg status:

• For HBeAg-negative patients, HCC risk increases with higher HBV DNA levels, plateauing at ≥5 log10 IU/mL.
• For HBeAg-positive patients, the association between HBV DNA levels and HCC risk is less pronounced.

HBsAg and HCC Risk:

HBsAg levels provide additional insight into HCC risk:

• In HBeAg-negative patients, high HBsAg levels (≥1000 IU/mL) are associated with increased HCC risk.
• In HBeAg-positive patients, a reverse association is observed. High HBsAg levels (≥10,000 IU/mL) are linked to a lower risk of HCC, particularly in the immune-tolerant phase.

Immune-Tolerant Phase and HCC:

Patients in the immune-tolerant phase (defined by HBeAg positivity, high HBV DNA, normal ALT, and no significant fibrosis) generally have a low short-term HCC risk. However, HCC risk increases over time due to factors like aging, phase transitions, or declining HBsAg levels. Long-term monitoring is essential, as a drop in HBsAg levels or a phase transition significantly elevates HCC risk.

Clinical Implications:

• Patients with HBeAg positivity and HBsAg levels ≥10,000 IU/mL are considered genuinely immune-tolerant and have a lower HCC risk. Those with lower HBsAg levels (<10,000 IU/mL) may have a higher risk and require closer monitoring or antiviral treatment.
• Dynamic monitoring, rather than relying solely on baseline characteristics, is crucial to account for the fluctuating nature of chronic HBV infection. Factors like age, fibrosis, family history of HCC, and metabolic conditions (e.g., diabetes) should also inform risk stratification and treatment decisions.

In summary, HBsAg and HBeAg levels, along with other clinical factors, play a critical role in predicting HCC risk and guiding management strategies for patients with chronic HBV.